Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending and single-dose safety, tolerability, and pharmacokinetics study of JNJ-77242113 in healthy Japanese and Chinese participants
jRCT2071210077Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of icotrokinra (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with adverse events (AEs) and Plasma concentration of JNJ-77242113. Started Nov 2021; status: active, not recruiting.
02
Drugs
icotrokinra
Beyond the preview
Go deeper on jRCT2071210077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210077.